This article is more than 5 years old. Information may no longer be current.
Latanoprostene sustains nocturnal, diurnal IOP lowering
Click Here to Manage Email Alerts
ORLANDO, Fla. — Once-daily latanoprostene bunod lowered IOP more than twice-daily timolol in an 8-week randomized crossover study of patients with open-angle glaucoma or ocular hypertension, according to a speaker here at the Association for Research in Vision and Ophthalmology meeting.
IOP was measured every 2 hours in 20 patients at baseline, at 4 weeks when crossover was implemented and at 8 weeks.
Latanoprostene bunod ophthalmic solution 0.024% was instilled once daily in one group and timolol maleate 0.5% was instilled twice daily in the other group. At crossover, regimens were switched.
Baseline IOP for inclusion was at least 22 mm Hg in one eye and less than 36 mm Hg in both eyes. Participants were housed in a sleep laboratory for 24 hours for each of the three measurement periods, and measurements were made with a pneumatonometer in both the supine and sitting positions during the day.
“Results showed that daytime efficacy of the timolol solution was less than [that of] latanoprostene,” John H. Liu, MD, said in the presentation.
Whereas latanoprostene bunod reduced both daytime and nighttime IOP, timolol maleate reduced only daytime IOP, according to the study. For both nocturnal and diurnal IOP measured in 24 hours after each crossover period, latanoprost reduced IOP a mean of 3.5 mm Hg and timolol reduced IOP a mean of 1.7 mm Hg.
Disclosure: Liu receives financial support from Aerie, Alcon, Allergan, Bausch + Lomb, NASA and Sensimed.